FINWIRES · TerminalLIVE
FINWIRES

BioMarin Pharmaceutical Q1 Revenue Beat Backed by Voxzogo Strength, Diversified Portfolio, Wedbush Says

By

BioMarin Pharmaceutical (BMRN) reported a Q1 beat on revenue, driven by Voxzogo and continued portfolio diversification amid emerging competition, Wedbush Securities said in a note Tuesday.

Voxzogo and total revenue came in at $220 million and $766 million, compared with the consensus of $216 million and $757 million, respectively. The decline from Q4 was mainly seasonal, and the company expects a stronger H2, due to recent acquisitions of Galafold and Pombiliti/Opfolda, the firm said.

The firm said the company has kept its Voxzogo guidance unchanged at $975 million to $1.025 billion, and despite rising competition, BioMarin plans to focus on execution to maintain its lead in achondroplasia using "robust" safety and efficacy data and broad early-treatment use.

"Recall management announced in January a goal of achieving sustained double-digit long-term total revenue compound annual growth rate into the 2030s, and we believe that BioMarin Pharmaceutical remains on track to deliver," the firm said.

Wedbush Securities has an outperform rating and $94 price target on BioMarin Pharmaceutical.

Price: $54.05, Change: $-1.42, Percent Change: -2.55%

Related Articles

Wire

IAC Q1 Loss Narrows, Revenue Falls; Shares Drop After Hours

IAC (IAC) reported a Q1 loss late Monday of $0.94 per diluted share, narrowing from the loss of $2.64 a year earlier.Analysts polled by FactSet expected a loss of $0.37.Revenue in the three months ended March 31 fell to $422.9 million from $481.7 million a year earlier.Analysts surveyed by FactSet expected $520.3 million.IAC shares fell 8.6% in after-hours trading.

$IAC
Wire

Vornado Realty Trust Q1 Non-GAAP FFO, Revenue Fall; Shares Drop After Hours

Vornado Realty Trust (VNO) reported Q1 non-GAAP funds from operations late Monday of $0.52 per diluted share, down from $0.63 a year earlier.Analysts polled by FactSet expected $0.51.Revenue in the three months ended March 31 fell to $459.1 million from $461.6 million a year earlier.Analysts surveyed by FactSet expected $431.7 million.Vornado shares fell 3% in after-hours trading.

$VNO
Wire

GeneDx Q1 Swings to Adjusted Loss, Revenue Rises; 2026 Revenue Guidance Lowered; Shares Fall

GeneDx (WGS) reported Monday Q1 adjusted loss of $0.28 per diluted share, swinging from an adjusted earnings of $0.31 a year earlier.Analysts polled by FactSet expected loss of $0.02.Revenue for the quarter ended March 31 was $102.3 million, up from $87.1 million a year earlier.Analysts surveyed by FactSet expected $112.5 million.For Q2, the company expects revenue of $110 million to $112 million. Analysts expect $130.3 million.The company now expects 2026 revenue of $475 million to $490 million, down from $540 million to $555 million expected earlier. Analysts expect $550.0 million.Shares of the company were down over 45% during after-hours activity.

$WGS